DATASET

Nanoparticle-based vaccines in clinical trial/use for COVID-19 and licensed for other pathogens

Collection: NANOSafety : Nanomaterial safety and nanomedicine 

Description

While several COVID-19 Nanoparticle-based vaccines have been developed during the past year, prior to this pandemic only a small number of NVs have been approved for human use (hepatitis, influenza, human papilloma virus) and were limited to the use of liposomes or virus-like particles. This content is focused on two categories of COVID-19 nanovaccines, protein and nucleic acids-based, containing “synthetic” NPs in their formulation. The Table reports the list of COVID-19 Nanovaccines currently in clinical trials or already approved for humans use. The list is organized into five different groups according to the types of nanocarrier used: ionizable lipid nanoparticles, proteolipid vehicles, polymeric nanoparticles, nanoemulsions, or virus like particles.

Contact

Email
Davide.magri (at) ec.europa.eu

Contributors

  • Luigi Calzolai
  • Sabrina Gioria
  • Davide Magrì

How to cite

Calzolai, Luigi; Gioria, Sabrina; Magrì, Davide (2021): Nanoparticle-based vaccines in clinical trial/use for COVID-19 and licensed for other pathogens. European Commission, Joint Research Centre (JRC) [Dataset] PID: http://data.europa.eu/89h/1575f3b3-f8e6-4f6c-a296-77e8d1be4ee1

Data access

COVID-19 NP-vaccines in clinical trial
Download 

Additional information

Published by
European Commission, Joint Research Centre
Created date
2021-04-06
Modified date
2021-04-14
Issued date
2021-04-01
Data theme(s)
Health
Update frequency
unknown
Identifier
http://data.europa.eu/89h/1575f3b3-f8e6-4f6c-a296-77e8d1be4ee1
Popularity
14 Nov 2021: 1 visits